The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group.

Authors :: Guilhot F
Guerci A
Fiere D
Harousseau JL
Maloisel F
Bouabdallah R
Guyotat D
Rochant H
Najman A
Nicolini F
Colombat P
Abgrall JF
Ifrah N
Brière J
Bauters F
Navarro M
Morice P
Bordessoule D
Vilque JP
Desablens B
Tertian G
Blanc M
Chastang C
Tanzer J
Source :: Bone marrow transplantation [Bone Marrow Transplant] 1996 May; Vol. 17 Suppl 3, pp. S29-31.
Publication Year :: 1996

Subjects :: Adult
Aged
Antineoplastic Agents adverse effects
Combined Modality Therapy
Drug Tolerance
France
Humans
Hydroxyurea administration & dosage
Interferon alpha-2
Interferon-alpha adverse effects
Middle Aged
Recombinant Proteins
Antineoplastic Agents administration & dosage
Cytarabine administration & dosage
Interferon-alpha administration & dosage
Leukemia, Myeloid, Chronic-Phase drug therapy
Leukemia, Myeloid, Chronic-Phase therapy
Randomized Controlled Trials as Topic methods

Tools